Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.

Experimental neurology - 1 Sept 2012

Kumar Ashish, Kneynsberg Andrew, Tucholski Janusz, Perry Giselle, van Groen Thomas, Detloff Peter J, Lesort Mathieu

Abstract excerpt

Huntington's disease (HD) is a devastating autosomal-dominant neurodegenerative disorder initiated by an abnormally expanded polyglutamine in the huntingtin protein. Determining the contribution of specific factors to the pathogenesis of HD should provide rational targets for therapeutic interven...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to Behavior, Animal
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP-Binding Proteins

Share to Huntington Disease

Share to Protein Glutamine gamma Glutamyltransferase 2

Share to Random Allocation

Share to Transglutaminases

Source

Open in PubMed Open full text

Identifiers

PMID: 22698685
DOI: 10.1016/j.expneurol.2012.05.015
PMCID: PMC3418489

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22698685-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.PMID 22698685Read ↗

Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.Semantic proximity Read ↗

Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate‐independent mechanismsSemantic proximity Read ↗

Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin.Semantic proximity Read ↗

Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s DiseaseSemantic proximity Read ↗

Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.Semantic proximity Read ↗

Transglutaminase 6 Is Colocalized and Interacts with Mutant Huntingtin in Huntington Disease Rodent Animal Models.Semantic proximity Read ↗

SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo.Semantic proximity Read ↗

Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage.Semantic proximity Read ↗

Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic miceSemantic proximity Read ↗

Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington diseaseSemantic proximity Read ↗

Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.Semantic proximity Read ↗

Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.